Abstract:Background: The outbreaks of emerging infectious diseases caused by pathogens such as SARS coronavirus, H5N1, H1N1, and recently H7N9 influenza viruses, have been associated with significant mortality and morbidity in humans. Neutralizing antibodies from individuals who have recovered from an infection confer therapeutic protection to others infected with the same pathogen. However, survivors may not always be available for providing plasma or for the cloning of monoclonal antibodies (mAbs).Methodology/Principal Findings: The genome and the immunoglobulin genes in rhesus macaques and humans are highly homologous; therefore, we investigated whether neutralizing mAbs that are highly homologous to those of humans (human-like) could be generated. Using the H5N1 influenza virus as a model, we first immunized rhesus macaques with recombinant adenoviruses carrying a synthetic gene encoding hemagglutinin (HA). Following screening an antibody phage display library derived from the B cells of immunized monkeys, we cloned selected macaque immunoglobulin heavy chain and light chain variable regions into the human IgG constant region, which generated human-macaque chimeric mAbs exhibiting over 97% homology to human antibodies. Selected mAbs demonstrated potent neutralizing activities against three clades (0, 1, 2) of the H5N1 influenza viruses. The in vivo protection experiments demonstrated that the mAbs effectively protected the mice even when administered up to 3 days after infection with H5N1 influenza virus. In particular, mAb 4E6 demonstrated sub-picomolar binding affinity to HA and superior in vivo protection efficacy without the loss of body weight and obvious lung damage. The analysis of the 4E6 escape mutants demonstrated that the 4E6 antibody bound to a conserved epitope region containing two amino acids on the globular head of HA.Conclusions/Significance: Our study demonstrated the generation of neutralizing mAbs for potential application in humans in urgent preparedness against outbreaks of new influenza infections or other virulent infectious diseases.

Generation of Human Neutralizing Monoclonal Antibodies Against the 2009 Pandemic H1N1 Virus from Peripheral Blood Memory B Lymphocytes.

Fully Human Broadly Neutralizing Monoclonal Antibodies Against Influenza A Viruses Generated from the Memory B Cells of a 2009 Pandemic H1N1 Influenza Vaccine Recipient.

Rapid Generation Of Human-Like Neutralizing Monoclonal Antibodies In Urgent Preparedness For Influenza Pandemics And Virulent Infectious Diseases

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses.

Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies Against Influenza A H5N1 Viruses.

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Generation, characterization, and protective ability of mouse monoclonal antibodies against the HA of A (H1N1) influenza virus

Intra-seasonal Antibody Repertoire Analysis of a Subject Immunized with an MF59®-adjuvanted Pandemic 2009 H1N1 Vaccine.

Pre-existing Immunity with High Neutralizing Activity to 2009 Pandemic H1N1 Influenza Virus in Shanghai Population.

Boosting Heterosubtypic Neutralization Antibodies in Recipients of 2009 Pandemic H1N1 Influenza Vaccine

Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain

Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.

Development of a Safe and Convenient Neutralization Assay for Rapid Screening of Influenza HA-specific Neutralizing Monoclonal Antibodies.

Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses.